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One of the most dramatic therapeutic advances 
in the history of medicine was the development 
and clinical implementation of antiretroviral 
therapy (ART) for HIV infection, a singular 
achievement that converted an almost univer-
sally fatal infection into a manageable chronic 
condition and provided a powerful interven-
tion to reduce the rate of transmission1. This 
advance originated with basic understanding 
of the molecular mechanisms of HIV replica-
tion and, by any standard, must be considered 
the quintessential paradigm of modern bench-
to-bedside research translation. Despite this 
accomplishment, the HIV epidemic continues 
to grow with the number of people in need of 
therapy increasing at a faster rate than the num-
ber of people with access to care. Moreover, 
even in resource-rich regions, the majority 
of HIV-infected people are not diagnosed, in 
care and/or on effective therapy2. Many factors 
account for this failure, including the expense 
of therapy, the side effects of therapy, and the 
difficulty in adhering to any regimen for years 
to decades. To tackle this epidemic and perhaps 
end AIDS in our time, two advances must be 
made—a vaccine that effectively and durably 
protects those at risk for HIV acquisition and 
a therapy that will eradicate the virus in those 
already infected.
The need for an effective HIV vaccine has 
been appreciated since the identification of 
HIV in the early 1980s, and the possibility of 
cure has been considered since the advent of 
effective ART more than a decade ago. Why, 
then, has progress on these most compelling 
needs been so slow? One obvious general dif-
ference between the successful development 
of ART and the lack of an effective vaccine or 
cure strategy is that solutions for the latter two 
problems cannot be found by the study of HIV 
or HIV-infected cells alone; instead, they must 
be formulated by analysis of the complex in vivo 
interactions between the virus and the host. 
For vaccine development, there are two 
crucial needs: first, to identify immunologic 
vulnerabilities of HIV (not an easy task, con-
sidering that HIV and its simian immuno-
deficiency virus precursors have evolved to 
efficiently evade immunity and therefore 
cause chronic active infection), and second, 
to develop a vaccine approach that safely and 
durably exploits such vulnerabilities3. For cure, 
the issues are even more complex, requiring 
both understanding of the nature and homeo-
stasis of the HIV reservoir in ART-suppressed 
subjects and development of approaches to acti-
vate latent virus and destroy all cells harboring 
replicating or potentially replicating HIV4,5. 
Whereas some aspects of this pathophysiol-
ogy can be investigated in test tubes, attaining 
the level of understanding necessary to ratio-
nally design prophylactic vaccines or clinical 
interventions for cure requires in vivo analysis. 
This is a daunting challenge, given that HIV is 
a human-specific virus that resides largely in 
difficult-to-reach tissues and that infects and 
destroys the immune system, leading to host-
virus interactions that are complex and difficult, 
if not impossible, to ‘untangle’.
Despite this complexity, human studies have 
led to crucial advances in understanding HIV 
transmission and persistence. For example, 
most recently, the Rv144 vaccine trial has pro-
vided evidence that HIV transmission might 
be vulnerable to vaccine-elicited immune 
responses6, and the increasing number of 
monoclonal antibodies isolated from HIV-
infected individuals has unequivocally showed 
that the humoral immune system can generate 
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is expensive, and thus experiments with appro-
priate statistical power invariably exceed the 
cost limits of common funding mechanisms. 
Facilities and expertise appropriate for these 
experiments, as well as the animals themselves, 
are quite limited, creating a bottleneck in which 
potentially key experiments are underpowered, 
delayed or not performed at all.
Translation of preclinical findings to the 
human system is also problematic, with clini-
cal investigators facing a number of barriers 
to success. Gaining knowledge about HIV 
transmission and persistence during therapy 
will require the study of mucosal and lym-
phoid tissues, but very few groups can rou-
tinely access and process such tissues. Clinical 
studies increasingly require teams of clinical 
and basic scientists, leading to uncertain aca-
demic advancement pathways and sources of 
support. Translational studies of new concepts 
are difficult to get through peer review, as they 
are typically small pilot studies. Investigation 
in humans also invariably involves risk that 
deters many funders and that draws attention 
from multiple oversight committees, which 
can lead to overwhelming regulatory hurdles. 
Finally, human studies aimed at defining the 
biology of HIV infection and/or selecting thera-
pies for future, more definitive clinical trials are 
expensive, requiring considerably more funds 
compared to laboratory- and small-animal 
model–based projects. As is increasingly rec-
ognized by the key funders of HIV vaccine and 
cure research, the traditional academic research 
model of independent laboratory- and ani-
mal model-based research groups funded by 
small project research grants will not, by itself, 
achieve the goals of the HIV vaccine and cure 
agendas. One of the key challenges of our field 
will be to adapt to the cooperative, multidisci-
plinary nonhuman primate model and clinical 
research-oriented science that will be necessary 
for success. —LP & SD
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of responses elicited by adenovirus 5 vaccine 
vectors to control infection of a CXCR4-tropic 
SIV-HIV hybrid virus and protect against the 
acute disease caused by this virus11,12 led to the 
expectation that the HIV version of this vaccine 
would provide substantial clinical protection. 
But the human trial of the adenovirus 5–HIV 
vaccine famously failed, a result that would 
have been predicted by analysis of the inability 
of this vaccine to protect against CCR5-tropic, 
chronic aggressive SIVs that cause an infection 
that more closely resembles HIV infection11,12. 
Hindsight suggests other mistakes that limited 
the usefulness of nonhuman primate models in 
past studies—notably, group sizes that were too 
small (leading to inconclusive studies) and the 
use of SIV challenge doses that were unrealisti-
cally high in vaccine studies, particularly via the 
intravenous route. In this regard, recent studies 
using repeated limited-dose mucosal challenge, 
which more closely reflects human sexual trans-
mission, and larger group sizes have revealed 
immune vulnerabilities of highly pathogenic 
SIV that could not have been appreciated with 
previous standard approaches, including a vac-
cine-mediated protection against acquisition of 
highly pathogenic SIV infection that has clear 
similarities with the protection observed in the 
Rv144 human vaccine trial3,13.
Nonhuman primates are not small humans 
and should not be considered a surrogate for 
humans or a ‘gatekeeper’ for human trials; how-
ever, analysis of appropriate nonhuman primate 
models can both define and answer crucial 
questions relevant to HIV vaccine development 
and cure, as well as explore the feasibility and 
efficacy of general approaches. Indeed, given 
the complexities of the relevant scientific issues 
and the myriad potential pathways to achieve 
therapeutic success, it can be argued that better 
exploitation of the nonhuman primate system 
(as well as further development of humanized 
mouse models) will be required. The clear need 
for coordination of nonhuman primate models 
and clinical research is not new, but obstacles to 
progress remain. Nonhuman primate research 
a potent, broadly HIV neutralizing antibody 
response7. Moreover, both the apparent cure 
of the ‘Berlin patient’ and the identification of 
post-treatment HIV controllers5 have showed 
that the HIV reservoir is potentially vulnerable 
to post-ART control and perhaps clearance. 
However, capitalizing on these observations will 
continue to be limited by inherent characteris-
tics of the human ‘model’, including a restricted 
ability to determine cause and effect by active 
in vivo intervention (any treatment must have 
both therapeutic potential and an acceptable 
safety profile), the fact that every human infec-
tion is with a different virus, and the fact that 
researchers often have limited access to human 
tissues other than blood. In addition, for trans-
mission analysis, natural HIV exposure is vari-
able and uncertain and can only be determined 
very generally in retrospect. 
Observational and interventional studies 
in humans can therefore take the field only so 
far—often far enough to raise questions and 
define desirable outcomes, but not sufficiently 
far to answer these questions or provide a clear 
path to therapeutically achieve these outcomes. 
Although iterative and adaptive clinical trials 
have been proposed as a solution to this conun-
drum8, the reality is that the questions are too 
many and the acceptable interventions too few 
to cover the necessary bases. Unless we are very 
lucky, identifying and optimizing an effective 
vaccine or cure strategy by human studies alone 
will take a very long time.
Thus, the first step in developing effec-
tive vaccine and cure strategies will invari-
ably involve use of a relevant animal model. 
Although some aspects of HIV pathophysiology 
can be modeled in humanized mice9,10, 
the most useful models for studies of HIV 
immuno- and pathobiology are based in non-
human primates3,11,12. Many nonhuman pri-
mate AIDS virus models exist, but they are not 
equivalent to each other, and not all models 
are appropriate for every scientific question. 
Indeed, misapplication of a model can lead the 
field seriously astray. For example, the ability 
Tackling influenza: diversity in viruses and hosts
What makes some influenza viruses able to 
efficiently transmit from person to person and 
others not? What determines the virulence of 
influenza viruses? Why does influenza cause 
severe disease in some people but not in others? 
How can we best respond to the emergence of 
a new influenza virus? These questions are the 
focus of active research, but influenza researchers 
face a number of specific challenges. The first is 
the diversity of influenza viruses in nature, which 
limits how generalizable findings are from one 
strain to other strains or subtypes and neces-
sitates experiments in different influenza virus 
backbones. Second, although several animal 
models can support the replication of influenza 
viruses, the extent to which they can be used to 
study disease or transmission varies, as does the 
availability of immunologic reagents to charac-
terize the host response to infection. In addition, 
although data from ferrets and monkeys are 
more relevant to humans than data from mice, 
the sample size in experiments with these species 
is often very small because they are expensive to 
purchase and house. Third, the unpredictability 
of the occurrence and severity of seasonal influ-
enza makes it challenging to plan and execute 
studies in humans—a well-designed study 
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may not yield data in a mild influenza season. 
Therefore, it is prudent to plan and fund clinical 
studies to span more than one influenza season.
Influenza viruses are constantly evolving by 
reassortment and mutation. Infection of a new 
host species, as evidenced by equine influenza 
viruses isolated from dogs or avian influenza 
viruses isolated from pigs or humans, can be 
sporadic and can fail to spread, or the virus can 
spread efficiently in the newly infected species. 
When the latter occurs in humans, a pandemic 
can ensue. Unfortunately, we do not yet under-
stand all of the viral and host factors that deter-
mine the transmissibility of influenza viruses in 
humans. With specific caveats in each case14, 
one can study transmission of human influenza 
viruses in humans15 and human and animal 
influenza viruses in animal models16. 
Despite the controversy (primarily due to 
dual-use concerns) surrounding the publication 
of two recent studies describing mutations in 
H5N1 viruses that conferred transmissibility in 
a ferret model17,18, transmissibility of influenza 
viruses is a crucial area for scientific research19 
that we cannot afford to set aside entirely. One 
possible approach to studying the transmissibil-
ity of animal influenza viruses with pandemic 
potential is to begin hypothesis testing with low-
virulence viruses, as such studies will not raise 
the same concerns as experiments with highly 
pathogenic H5N1 viruses. But limited experi-
ments with a highly virulent virus (conducted 
safely under appropriate containment after care-
ful risk assessment) will be needed to generate 
definitive proof. Such studies will require com-
munication between influenza virologists and 
biosafety and biosecurity experts as well as the 
education of the scientific and general publics 
on the importance of this research, with an 
emphasis on the safeguards that are in place.
Animal models have been used to answer 
many questions in influenza biology, rang-
ing from pathogenesis and immune response 
to transmission and control measures. Each 
model has its pros and cons, and none faithfully 
replicates the clinical experience in humans. In 
part, the gap between data from animal models 
and the clinical experience is because laboratory 
research is carried out in influenza-naïve experi-
mental animals, whereas humans beyond early 
childhood have prior experience with influenza. 
Studies in naïve animals led to an overestima-
tion of the virulence of the 2009 pandemic H1N1 
virus for humans20,21 and to the prediction that 
two doses of vaccine would be required to immu-
nize the population. As it turned out, as a result 
of previous priming, a single dose of vaccine 
was sufficient to immunize all but very young 
children. Prior exposure should be modeled in 
animal models22, and models should be judi-
ciously selected to address specific research ques-
tions rather than a one-size-fits-all approach in 
which data from ferrets or nonhuman primates 
are emphasized to the exclusion of other data.
The identification of viral determinants of 
virulence and an understanding of the events 
triggered in the host can lead to the development 
of new therapeutic agents. Viral determinants of 
virulence are typically identified by comparing 
pairs of influenza viruses with dichotomous 
virulence (and sequences) in an experimental 
animal model23,24. Surveillance programs can 
monitor viruses for genetic changes that are 
associated with virulence. The challenge lies 
in synthesizing this information with a focus 
on the phenotype of virulence rather than the 
genotype and in exploring how the mutations 
alter virulence to determine whether they are 
broadly applicable or unique to a particular iso-
late or clade.
Why does influenza cause severe disease in 
some people and not in others? A multidisci-
plinary approach that examines the influence of 
genetics, immunology and virus-host interac-
tions in natural history studies25 or human chal-
lenge studies26 will probably shed light on this 
question. For human challenge studies, we need 
access to challenge virus preparations that meet 
regulatory requirements, to appropriate inpa-
tient facilities and to a mechanism to maintain 
a pipeline of challenge virus pools to which sub-
jects are susceptible. All of these require long-
term commitment and funding.
The scientific, medical and public health 
communities must be able to respond rapidly 
to the emergence of a novel virus, and the only 
way to do this is to have a network in place that 
can be activated at short notice. A good example 
is the MOSAIC (Mechanisms of Severe Acute 
Influenza Consortium) network, which under-
took clinical evaluation of the 2009 pandemic 
H1N1 virus in the UK26. Despite the operational 
hurdles, we are at an exciting time in influenza 
research because increasingly sophisticated 
technology is becoming available to address 
complex questions in biology, medicine and 
public health. Rational discourse and applica-
tion of specific models to elucidate the bio-
logical mechanisms underlying virulence and 
transmission will facilitate our understanding 
of human influenza. —KS
COMPETING FINANCIAL INTERESTS 
The author declares no competing financial interests.
Discovering and uncovering viruses
The methodical search for unknown viruses—
or ‘virus discovery’—promises quick answers 
and shortcuts in the quest for viral disease eti-
ologies. Understanding viral causation can be 
key to diagnostics, prevention and treatment of 
a disease. But the growing discrepancy between 
expectations and results in this field poses a 
crucial question that must be addressed: what 
can be learned from all of the new viruses—
their sequences in particular—identified by 
new technologies such as next-generation 
sequencing? First, differences between viruses 
and viral sequences must be discussed and 
clarified. About 20 years ago, in the early days 
of PCR diagnostics, the phenomenon of reac-
tion products ‘hopping’ between PCR tubes left 
virologists hesitant to accept the existence of 
new viruses until isolates were obtained and 
characterized. The advanced technology used 
nowadays allows us to find sequences that often 
form new phylogenetic clades clearly different 
from laboratory strains, so they are unlikely 
to be contamination artifacts. Although next- 
generation sequencing will also detect inte-
grated defective viruses and viral genome fos-
sils27, most of the encountered new sequences 
represent true viruses with the potential to 
replicate and cause disease in humans.
The threshold beyond which viruses can be 
declared ‘new’ still sparks debates27,28, and these 
will continue as long as we lack general and pro-
spective criteria to classify new viruses. Our 
improved knowledge of viral diversity obtained 
through virus discovery, however, should soon 
enable a much more general approach to viral 
taxonomy based on full-genome phylogenies29. 
Such more holistic taxonomy will have func-
tional implications, for example when it comes 
to the investigation of cellular antiviral targets 
whose activities could be conserved within rea-
sonably delineated taxonomic units of viruses30.
In clinical virus discovery, there have been 
plenty of studies on respiratory illness and 
diarrhea—acute conditions where viruses can 
be caught red-handed in the body. For other 
diseases, such as multiple sclerosis and other 
chronic and degenerative diseases, we are far 
from solving their mystery etiologies, as if there 
is any virus involved, it may be long gone once 
symptoms develop31. The only traces of viruses 
might exist in immunity patterns such as anti-
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bodies or primed immune cells. Although these 
patterns have already been investigated with the 
available methods, we have not seen the same 
technical revolution in immune diagnostics as 
in molecular detection, where next-generation 
sequencing has enhanced the depth of data by 
orders of magnitude. Therefore, our techni-
cal capability to find new virus sequences is 
no longer the bottleneck; instead, our biggest 
challenge is to appreciate the medical relevance 
of our results. Traditionally, it was believed that 
viruses are not part of the normal flora, caus-
ing a sentiment that newly discovered viruses 
should all be pathogens. But more recent stud-
ies have shown that the normal human micro-
bial flora probably includes nonpathogenic and 
even symbiotic viruses32. In addition, innocu-
ous contaminant viruses can also be detected 
in humans, such as plant, arthropod and fish 
viruses, most likely derived from diet33.
Virus discovery studies must therefore entail 
appropriate clinical validation with statistical 
power to confirm the absence of new viruses 
in healthy control groups. We currently lack 
data on pathogenicity for a whole range of new 
viruses, including cardioviruses, klassevirus/
salivirus, cosaviruses, several new anello-, 
circo- and cycloviruses (and other small single-
stranded DNA viruses) as well as an expand-
ing range of new polyomaviruses. The human 
bocavirus, discovered in 2005 and heavily 
investigated since, can be seen as a paradigm for 
this problematic field. The majority of studies 
on human bocavirus have focused on patients 
with disease, but those studies including a suf-
ficient range of differential diagnoses found tre-
mendous rates of co-infection with a plethora of 
‘professional’ respiratory and enteric pathogens, 
suggesting the virus to be a bystander34.
Virus discovery has also extended to animal 
viruses and the investigation of viral reservoirs, 
which has raised big expectations as to the trans-
lational value of these data. Although some of 
these studies are aimed primarily at understand-
ing the ecology and evolution of viruses35, there 
is hope (and there are big promises) that virus 
discovery may give us a head start against the 
next pandemic to emerge36. It is reasonable to 
endeavor to make a census of all viruses lurking 
in animal reservoirs, as this will help identify 
viruses during future outbreaks. For example, 
our expanded knowledge about bat-borne coro-
naviruses has made the identification of a new 
human coronavirus that recently emerged in the 
Arabian Peninsula much easier than the identifi-
cation of the SARS coronavirus 10 years ago37,38. 
But the sequencing of reservoir-borne viruses 
can only be a very first step in viral risk assess-
ment, as complex processes such as viral entry 
and virus-host cooperation at the cellular level, 
as well as the many components of epithelial and 
systemic host defense versus viral immune eva-
sion, also determine whether a virus can infect 
and spread in humans. The unfiltered presenta-
tion of new viruses can create an unjustified air 
of alarm, and we should therefore investigate 
biological functions to provide surrogates of 
transmission risk along with initial descriptions 
of reservoir-borne viruses. Initial studies work-
ing along these lines have now been published, 
such as the description of a new henipavirus that 
seems to lack an essential anti-interferon pro-
tein, or a new influenza virus from bats whose 
replicative proteins seem to function in the con-
text of human cells39,40.
An improved viral sequence inventory may 
address one of the largest technical challenges 
currently encountered in viral discovery: the 
lack of template sequences against which we 
can compare our data. We routinely see next-
generation sequencing reads that cannot be 
aligned to any known member of public gene 
databases because their genetic distance to any 
banked virus is just too large. There is still a 
genetic terra incognita where we cannot recog-
nize next-generation sequencing reads as viral 
sequences. The shortness of these reads also 
precludes more sensitive database comparisons 
based on prediction of encoded protein struc-
ture. Thus, even though the collection of res-
ervoir animal ‘metaviromes’ seems like a large 
effort with little direct utility, it may in fact con-
stitute the most direct way to better understand 
the human virome.
Our collective current approach to viral dis-
covery is dominated by the fascination around 
new technology, which is evolving at a rapid 
pace. Nevertheless, the results we obtain are still 
closer to raw data than to conclusive analyses of 
etiological problems. More clinical and func-
tional investigations must be included routinely 
in discovery studies to prevent misinterpreta-
tion of data and to fulfill our most elementary 
translational claim—the identification of mean-
ingful viral etiologies. —CD
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Filling the holes in RSV prevention and treatment
Respiratory syncytial virus (RSV) is a lead-
ing cause of bronchiolitis and pneumonia in 
children. The WHO estimated that in 2005, 
RSV infection resulted in 34 million cases of 
acute lower respiratory disease in children 
less than 5 years old, with about 10% requir-
ing hospital admission and 66,000–199,000 
deaths41. Despite years of intense study, there 
are no vaccines to prevent RSV disease and few 
options for treatment. Although passive admin-
istration of virus-neutralizing antibodies can 
reduce RSV-related hospitalizations in infants 
at high risk for RSV disease42–44, translation of 
this protective correlate into a safe and effective 
pediatric vaccine has not yet occurred.
Several problems account for this lack of suc-
cess. The highest rate of RSV hospitalization 
is among infants less than 3 months of age45, 
which is when the ability to elicit a strong anti-
body response to vaccine may be compromised 
by the presence of maternal antibodies and the 
immaturity of the infant immune system. In 
addition, vaccine formats that might be capa-
ble of eliciting strong RSV-neutralizing serum 
antibody responses in children, comparable to 
those achieved with antibody immunoprophy-
laxis (such as parenteral administration of prop-
erly folded viral protein subunits formulated 
with adjuvant), would be difficult to clinically 
develop, at least in part, because of concerns 
that these vaccines may potentiate RSV dis-
ease. In the 1960s, a formalin-inactivated, 
alum-adjuvanted whole-virus vaccine was 
tested in infants and children; however, it not 
only failed to protect against RSV disease but 
also resulted in immune-mediated disease 
enhancement46. The subsequent develop-
ment of animal models of RSV vaccine disease 
enhancement suggested that parenteral vac-
cination of RSV-naïve animals with subunit 
vaccines could result in enhanced pulmonary 
pathology after RSV challenge47. In contrast, 
live, attenuated RSV vaccines and chimeric 
viruses expressing RSV antigens48,49 did not 
seem to enhance the risk for RSV disease in 
vaccinated animals. It is these live, intranasally 
administered vaccine candidates that have 
advanced into clinical studies in seronegative 
infants (ClinicalTrials.gov NCT00767416, 
NCT00686075 and NCT01459198).
However, identifying immune correlates of 
activity and protection will probably be difficult 
for live intranasal vaccines that remain localized 
in the airways. Only 44% of infants intranasally 
vaccinated with a live, attenuated RSV vaccine 
candidate had detectable serum antibody to 
RSV, in spite of evidence that most of the vac-
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that act on the virus and not the host may pro-
vide the safest strategy for treating young chil-
dren with RSV disease.
Although RSV is largely known as a pediat-
ric infection, it also causes substantial disease 
in the elderly, adults with chronic heart and 
lung disease and those who are immunosup-
pressed, specifically with T cell deficiencies52. 
As the humoral response to RSV seems intact 
in adult patients53, it is likely that effective vac-
cine strategies targeting adult populations will 
differ from those for infants. The presence of 
RSV-neutralizing antibody in adults would pre-
vent infection of the upper airways with the live, 
attenuated RSV vaccines that are being devel-
oped for seronegative children. Development 
of therapeutic interventions for adults will 
require rapid diagnostics appropriate for this 
population, as adults shed lower quantities of 
virus and for shorter periods of time compared 
to children54. Many RSV diagnostics developed 
for pediatrics (there are about 20 different com-
mercial RSV diagnostic kits) are insufficiently 
sensitive to detect RSV in adults. PCR meth-
odologies that have allowed detection of RSV 
in adults are extremely sensitive and have led 
to observations by some investigators of per-
sistent RSV infection, particularly in adults 
with chronic obstructive pulmonary disease55. 
Persistent infection with RSV remains a contro-
versial topic that, if substantiated and found to 
be clinically meaningful, could have profound 
implications for the development of RSV vac-
cines and therapies.
RSV is a complex pathogen that poses mul-
tiple translational challenges. These include the 
lack of a small-animal model that recapitulates 
human infection and disease, the different 
human target populations requiring different 
diagnostics and intervention strategies, and 
the fact that its pathogenesis and immune 
responses must be studied in a rather inacces-
sible compartment such as the human airway. 
As is the case with other complex pathogens, it 
will be the consolidation of data from multiple 
sources each of which independently provides 
an incomplete picture, along with the applica-
tion of new technology platforms, that will lead 
to vaccines and therapies for RSV. In addition, 
because RSV largely affects the very young 
and the old, success against RSV will require a 
commitment to better understanding immune 
responses to infection early and late in life. —JS
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cine recipients were protected against subse-
quent challenge with the vaccine virus50. Past 
experience with live, attenuated influenza vac-
cines illustrates the difficulty of identifying cor-
relates of protection for vaccines administered 
locally. Numerous assays have been evaluated 
over the past 20 years, including various mea-
sures of serum antibody responses, nasal IgA 
and interferon-g enzyme-linked immunospot 
assays; however, to date no absolute correlate of 
protection has been identified for these influenza 
vaccines. The problem may be that current assay 
systems are insufficiently sensitive to detect local 
immune responses. Although it is possible to 
develop a vaccine without a correlate of activity, 
it is challenging to do so. The inability to show 
that a vaccine induces a robust immune response 
in the majority of recipients makes the decision 
to proceed into large, expensive efficacy studies 
very difficult. If a vaccine is licensed and no cor-
relate of immune protection is established, the 
demonstration that subsequent manufacturing 
and/or formulation modifications do not have a 
negative impact on vaccine potency requires the 
conduct of additional efficacy studies.
It would be highly desirable to have an RSV 
therapeutic capable of reducing disease severity, 
halting disease progression and/or shortening 
the time to disease resolution for RSV-infected 
children after they are diagnosed. This is espe-
cially important with the continuing absence of 
a RSV vaccine. A central concern in RSV antivi-
ral development, however, is whether any anti-
viral compound can affect disease progression 
or outcome when administered after a child is 
symptomatic. A recent study of RSV infection in 
the US indicated that children brought to emer-
gency departments and pediatric offices often 
already have moderately severe disease51. It has 
been proposed that RSV pathogenesis, which 
involves airway obstruction by exudate contain-
ing damaged epithelial cells, is driven both by 
viral replication and the host immune response 
to infection, so that targeting one and not the 
other would fail to provide therapeutic benefit. 
Much of what we understand about RSV patho-
genesis, and the role of host responses in RSV 
pathology, comes from mouse and cotton rat 
infection models. But these animal models are 
imperfect at best and are unlikely to accurately 
reflect disease progression in children. The con-
tinuing debate about whether RSV replication 
drives disease after respiratory symptoms are 
apparent may be discouraging the development 
of new antiviral compounds for RSV. Antivirals 
capable of shutting down virus replication are 
more likely to be effective later in the disease 
course than agents designed to block virus entry 
and spread, and it is through clinical testing of 
replication inhibitors that the drivers of RSV 
disease may be elucidated. Furthermore, agents 
np
g
© 
20
13
 N
at
ur
e A
m
er
ic
a,
 In
c.
 A
ll 
rig
ht
s 
re
se
rv
ed
.
